ESSA Pharma Inc. Files Definitive Proxy Statement
| Field | Detail |
|---|---|
| Company | Essa Pharma Inc. |
| Form Type | DEFA14A |
| Filed Date | Aug 6, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, regulatory-filing, pharmaceutical
TL;DR
ESSA Pharma filed its proxy statement, get ready for shareholder votes.
AI Summary
ESSA Pharma Inc. filed a DEFA14A on August 6, 2025, reporting on events from August 5, 2025. The filing is a definitive proxy statement, indicating it concerns a shareholder meeting or vote. The company, incorporated in British Columbia, Canada, operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing is a standard regulatory disclosure for public companies, informing shareholders about upcoming decisions or votes that could impact the company's direction.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEFA14A) and does not inherently present new risks.
Key Players & Entities
- ESSA Pharma Inc. (company) — Filer of the DEFA14A
- August 6, 2025 (date) — Filing date of the DEFA14A
- August 5, 2025 (date) — Earliest event reported date
- Vancouver, British Columbia, Canada (location) — Principal executive offices location
FAQ
What type of filing is this DEFA14A for ESSA Pharma Inc.?
This filing is a Definitive Proxy Statement (DEFA14A) filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
When was the DEFA14A filed by ESSA Pharma Inc.?
The DEFA14A was filed on August 6, 2025.
What is the earliest event date reported in this filing?
The earliest event reported in this filing is August 5, 2025.
Where are ESSA Pharma Inc.'s principal executive offices located?
ESSA Pharma Inc.'s principal executive offices are located at Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada.
What is the standard industrial classification for ESSA Pharma Inc.?
ESSA Pharma Inc. is classified under Pharmaceutical Preparations [2834].
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on August 6, 2025 regarding ESSA Pharma Inc..